Under an alliance framework with AstraZeneca, Merck, and Eli Lilly and Company leading as founding participants, the Atlas is ...

Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

Fill out the form below and we'll send your colleague an invitation to the "Enhancing Predictive Capabilities With Complex Human Cell-Based Models" event. Advanced in vitro models are reducing ...

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

SAN FRANCISCO & PALO ALTO, Calif. & REDWOOD CITY, Calif., January 12, 2026--Tahoe Therapeutics, Arc Institute, and Biohub ...

Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...

Live-cell imaging, integrated with AI/ML, enhances phenotypic screening, improving drug discovery and lead optimization. European companies are pioneering live-cell imaging technologies, advancing in ...

Advanced 3D cell models recreate the complexity of human tissues, enabling researchers to examine tumor progression, probe neurological disorders, and assess therapeutic candidates. By capturing the ...

Ginkgo Bioworks has announced the launch of the Virtual Cell Pharmacology Initiative (VCPI) through Ginkgo Datapoints. This open-source platform is designed to build a standardized framework for ...